NATTO: VITAMIN K2 VS VITAMIN K1 PAPER PUBLISHED IN INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

09:47
New review paper, completed as part of INTRICARE and EVOluTION research grants,
advances argument for Vitamin K2-specific RDI to benefit more consumers.
Oslo, Norway and Edison, NJ (26 FEB 2019) - The International Journal of
Molecular Sciences has published a new review paper examining the differences
between vitamins K1 and K2, showing that based on its very molecular structure
K2 is available beyond the liver to support systems like the bone and
vasculature through proper calcium utilization. The review paper, the result of
the INTRICARE and EVOluTION grants awarded to NattoPharmas International
Research Network by the European Union within the Horizon 2020 Marie Sklodowska
-Curie research and innovation program, is an important step in establishing the
need for a Vitamin K2-specific recommended daily intake (RDI).

The paper is significant because it is a necessary step towards recognizing the
importance of a vitamin K2-specific RDI, an endeavor NattoPharma is currently
spearheading with the help of its research partners, according to NattoPharma
Chief Medical Officer Dr. Hogne Vik.

This review paper continues to explore the differences between Vitamin K1 with
its known benefit for coagulation and the newly recognized benefits of Vitamin
K2 also to function extrahepatically to support bone and cardiovascular health,
says Vik. Practically, the body of evidence today supports a dominant role for
Vitamin K2 in the inhibition of calcification of soft tissues because of its
better bioavailability and bioactivity. Observational studies and gold standard
double-blind, placebo-controlled trials show that Vitamin K2 may inhibit
vascular calcification and even hold progression of vascular stiffness.

Recognition of Vitamin K2s benefits as strong and significant elucidated
inhibitor of vascular and soft tissue calcification is one of the core reasons a
separate RDI should be established, Vik adds. We are proud that our
partnership with Maastricht University and these prestigious grants have given
us an opportunity to further the understanding of the necessity of obtaining
adequate vitamin K2 for human health.

Expanding global understanding for the need for additional Vitamin K2 in a diet
to overcome insufficient intake and address significant health concerns will
certainly increase the number of consumers that MenaQ7 can significantly
benefit.

According to the authors, the paper Vitamin K: Double Bonds beyond Coagulation
Insights into Differences between Vitamin K1 and K2 in Health and Disease, is
the first to highlight differences between isoforms vitamin K1 and K2 by means
of source, function, and extrahepatic activity. Prof. Schurgers states that
functions of K2 are proving to be beneficial with regard to cardiovascular
diseases and bone metabolism, yet there is a growing body of evidence suggesting
vitamin K2 is involved in multiple cellular processes and might have a
protective role in various organs throughout the human body. To that end it is
important to consider an RDI reflective of these additional roles.

When exploring the non-coagulation, extrahepatic activities of vitamin K, it is
clear that K2 in its various forms is the highlight of such activity. Therefore,
although history and nomenclature have classed K1 and K2 into the same category,
these molecules can have a very different action in the body, says Prof.
Schurgers, Professor of Biochemistry of Vascular Calcification and Vice Chair of
Biochemistry at the Cardiovascular Research Institute Maastricht (CARIM),
Maastricht University

Source Url: https://newsweb.oslobors.no/message/470537


© Oslo Børs